: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Leukemia

Free Subscription

Articles published in Blood
Retrieve available abstracts of 436 articles:
HTML format

Single Articles

March 2026

DERMER K, Richardson AI
Pediatric acute erythroid leukemia with NUP98::KDM5A fusion.
Blood. 2026;147:1237.
PubMed

MUJOLLARI J, Estruch M, Khadgawat P, Choudhary S, et al
The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.
Blood. 2026;147:1229-1236.
PubMed Abstract available

DI GIACOMO D, Polonen P, Bardelli V, Kimura S, et al
Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.
Blood. 2026 Mar 6:blood.2025031402. doi: 10.1182/blood.2025031402.
PubMed Abstract available

PLATZBECKER AS, Georgi JA, Middeke JM, Sockel K, et al
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Blood. 2026;147:1098-1110.
PubMed Abstract available

KNAPPER S, Dillon LW, Babu M, Thomas A, et al
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.
Blood. 2026;147:1048-1057.
PubMed Abstract available

RHEIN S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, et al
A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.
Blood. 2026;147:1058-1069.
PubMed Abstract available

BECILLI M, Merli P, Algeri M, Del Bufalo F, et al
Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia.
Blood. 2026 Mar 3:blood.2025032299. doi: 10.1182/blood.2025032299.
PubMed Abstract available

February 2026

PARFENOVA EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, et al
Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.
Blood. 2026 Feb 26:blood.2025031202. doi: 10.1182/blood.2025031202.
PubMed Abstract available

HIMONAS E, de Beauchamp L, Zerbst D, Desmares-Romain E, et al
A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.
Blood. 2026 Feb 24:blood.2024027853. doi: 10.1182/blood.2024027853.
PubMed Abstract available

ATTARDI E, Gray N, Lewis S, Boals M, et al
Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals.
Blood. 2026;147:897-901.
PubMed Abstract available

LING T, O'Brien C, St-Germain JR, Rondeau V, et al
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.
Blood. 2026;147:863-876.
PubMed Abstract available

TURKALJ S, Radtke FA, Stoilova B, Mecklenbrauck R, et al
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
Blood. 2026;147:613-632.
PubMed Abstract available

January 2026

RANASINGHE D, Lin WY, Fordham SE, Alharbi AA, et al
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.
Blood. 2026 Jan 29:blood.2025031266. doi: 10.1182/blood.2025031266.
PubMed Abstract available

PINTON A, Courtois L, Delafoy M, Bonnet MF, et al
Homeodomain-driven oncogenic diversion to a TCRgammadelta phenotype in T-cell Acute Lymphoblastic Leukemia.
Blood. 2026 Jan 27:blood.2025030626. doi: 10.1182/blood.2025030626.
PubMed Abstract available

GOTLIB J
Introduction to a How I Treat series on chronic myeloid leukemia.
Blood. 2026;147:319-320.
PubMed

MAURO MJ
How I treat advanced phases of CML.
Blood. 2026;147:369-378.
PubMed Abstract available

SOVERINI S, Castagnetti F
How I evaluate and treat resistance and relapse in CML.
Blood. 2026;147:337-346.
PubMed Abstract available

LEYTE-VIDAL A, Shah NP
How I individualize frontline treatment for chronic-phase CML.
Blood. 2026;147:329-336.
PubMed Abstract available

POPESCU B, Jones MF, Piao M, Tran E, et al
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Blood. 2026;147:276-289.
PubMed Abstract available

SHARPE-DAVIDSON WF, Wan YO
Acute promyelocytic leukemia diagnosed on soft tissue biopsy: a rare extramedullary presentation.
Blood. 2026;147:215.
PubMed

GUARNERA L, Wahida A, Gurnari C, Hutter S, et al
Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.
Blood. 2026;147:197-208.
PubMed Abstract available

DOHNER H, Spath D, Saadati M, Fiedler W, et al
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
Blood. 2026 Jan 5:blood.2025030722. doi: 10.1182/blood.2025030722.
PubMed Abstract available

KEESHAN K
Fetal defense against leukemia: a developmental shield.
Blood. 2026;147:7-8.
PubMed

WEI AH, Iland HJ, DiNardo CD, Reynolds J, et al
Measurable residual disease intervention in AML: a new therapeutic horizon.
Blood. 2026;147:13-23.
PubMed Abstract available

MENDOZA-CASTREJON J, Yang W, Denby E, Wang HC, et al
Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.
Blood. 2026;147:61-72.
PubMed Abstract available

December 2025

NISHIMURA K, Isobe T, Shigehiro T, Nomura M, et al
Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.
Blood. 2025 Dec 29:blood.2024026928. doi: 10.1182/blood.2024026928.
PubMed Abstract available

SIMON F, Ligtvoet R, Bohn JP, Nosslinger T, et al
Acalabrutinib treatment for older (aged >/=80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.
Blood. 2025;146:3153-3162.
PubMed Abstract available

AL-SAWAF O, Locher BN, Christen F, Hablesreiter R, et al
The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.
Blood. 2025 Dec 23:blood.2025029905. doi: 10.1182/blood.2025029905.
PubMed Abstract available

WILSON NK, Gottgens B
Breaking the silence: restoring CEBPA to fight leukemia.
Blood. 2025;146:3014-3015.
PubMed

FLEMING TJ, Antoszewski M, Lambo S, Gundry MC, et al
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.
Blood. 2025;146:3019-3035.
PubMed Abstract available

DELAFOY M, Bonnet MF, Lengline E, Cieslak A, et al
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/beta-catenin vulnerability in T-ALL.
Blood. 2025;146:3036-3049.
PubMed Abstract available

CORTES JE, Hughes TP, Wang J, Kim DW, et al
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
Blood. 2025 Dec 15:blood.2025029210. doi: 10.1182/blood.2025029210.
PubMed Abstract available

ZHANG L, Kang H, Valerio M, Hoang DH, et al
Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia.
Blood. 2025 Dec 15:blood.2025029875. doi: 10.1182/blood.2025029875.
PubMed Abstract available

CLOOS J, Valk PJM, Thiede C, Dohner K, et al
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.
Blood. 2025 Dec 15:blood.2025031480. doi: 10.1182/blood.2025031480.
PubMed Abstract available

MEYER E, Salhotra A, Gandhi A, Pantin J, et al
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.
Blood. 2025 Dec 12:blood.2025031313. doi: 10.1182/blood.2025031313.
PubMed Abstract available

SOUTO FILHO JTD, Paulo AB
Promyelocyte maturation arrest after rituximab-induced late-onset neutropenia mimicking acute promyelocytic leukemia.
Blood. 2025;146:3003.
PubMed

Marchand T, Lamy T, Loughran TP Jr. A modern view of LGL leukemia. Blood. 2024;144(18):1910-1923.
Blood. 2025;146:2844.
PubMed

SHANMUGANATHAN N, Yeung DT, Wadham C, Fernandes A, et al
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.
Blood. 2025;146:2821-2832.
PubMed Abstract available

PAN J, Zhao L, Zhang Y, Seery S, et al
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial.
Blood. 2025;146:2745-2757.
PubMed Abstract available

November 2025

Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.
Blood. 2025;146:2729.
PubMed

PARISI X, Loghavi S
NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation.
Blood. 2025;146:2612.
PubMed

RAJ R, Catueno S, Gibson A, McCall D, et al
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.
Blood. 2025;146:2608-2611.
PubMed Abstract available

BUECHNER J, Poetschger U, Bader P, Yesilipek MA, et al
Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.
Blood. 2025 Nov 19:blood.2025030951. doi: 10.1182/blood.2025030951.
PubMed Abstract available

Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
Blood. 2025;146:2493.
PubMed

AL-SAWAF O, Furstenau M, Giza A, Robrecht S, et al
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Blood. 2025;146:2406-2416.
PubMed Abstract available

CHEN C, Cai J, Wu X, Hu Q, et al
Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL.
Blood. 2025;146:2417-2427.
PubMed Abstract available

AZEVEDO RS, Jabbour E, Kantarjian HM, Lavu S, et al
Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.
Blood. 2025 Nov 10:blood.2025030498. doi: 10.1182/blood.2025030498.
PubMed Abstract available

STELLJES M, Middeke JM, Bug G, Wagner-Drouet EM, et al
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.
Blood. 2025;146:2293-2305.
PubMed Abstract available

KAWANO G, Ikeda R, Ishihara D, Shima T, et al
Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.
Blood. 2025 Nov 5:blood.2025030209. doi: 10.1182/blood.2025030209.
PubMed Abstract available

October 2025

KRUER TL, Quintana A, Newman H, Ferrall-Fairbanks M, et al
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.
Blood. 2025;146:2244-2258.
PubMed Abstract available

BURGER JA, Barr PM, Robak T, Owen C, et al
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
Blood. 2025;146:2168-2176.
PubMed Abstract available

SEMBA Y, Yamauchi T, Bauer DE, Ogawa S, et al
The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.
Blood. 2025 Oct 29:blood.2025028918. doi: 10.1182/blood.2025028918.
PubMed Abstract available

FETSCH V, Schwobel LF, Ozyerli-Goknar E PhD, Stell AV, et al
Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.
Blood. 2025 Oct 27:blood.2025029712. doi: 10.1182/blood.2025029712.
PubMed Abstract available

BOISSEL N, Chevret S, Rigal-Huguet F, Leguay TT, et al
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.
Blood. 2025 Oct 24:blood.2025029611. doi: 10.1182/blood.2025029611.
PubMed Abstract available

DUNCAVAGE E, Spencer D
Leukemic fusion: partners and mutations shape NUP98r leukemia.
Blood. 2025;146:2017-2018.
PubMed

SHADMAN M, Davids MS
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor.
Blood. 2025;146:2029-2036.
PubMed Abstract available

SHI Y, Jiang Q, Li L, Zuo Y, et al
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1.
Blood. 2025;146:2088-2101.
PubMed Abstract available

LASZIG S, Diederichs A, Salzmann-Manrique E, Schuschel K, et al
CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial.
Blood. 2025 Oct 21:blood.2025030775. doi: 10.1182/blood.2025030775.
PubMed Abstract available

LAM K, Kim YJ, Tan EL, Ong CM, et al
The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia.
Blood. 2025 Oct 20:blood.2024026749. doi: 10.1182/blood.2024026749.
PubMed Abstract available

THAKUR RK, Karlsson G
Insights from Single-cell Omics: Cellular Heterogeneity as a Foundation of Clinical Outcome in Chronic Myeloid Leukemia.
Blood. 2025 Oct 17:blood.2025029011. doi: 10.1182/blood.2025029011.
PubMed Abstract available

HANTEL A, Wang Y, Cronin A, Khan I, et al
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials.
Blood. 2025 Oct 16:blood.2025030741. doi: 10.1182/blood.2025030741.
PubMed Abstract available

CHIRIAC R
Acute myeloid leukemia mimicking mature lymphoid morphology.
Blood. 2025;146:2005.
PubMed

GUO M, Memis T, Ehrmann AS, Pittrof A, et al
A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL.
Blood. 2025;146:1936-1949.
PubMed Abstract available

SHI M, Rech KL
T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma.
Blood. 2025;146:1868.
PubMed

OTHMAN J, Potter N, Freeman SD, McCarthy N, et al
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Blood. 2025;146:1862-1867.
PubMed Abstract available

PASTOORS D, Havermans M, Mulet-Lazaro R, Smeenk L, et al
MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.
Blood. 2025 Oct 8:blood.2025028914. doi: 10.1182/blood.2025028914.
PubMed Abstract available

SCHROEDER B, Yuan CM, Wang HW, Mohindroo C, et al
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.
Blood. 2025 Oct 8:blood.2025031243. doi: 10.1182/blood.2025031243.
PubMed Abstract available

BROWN JR, Nguyen B, Desikan SP, Won H, et al
Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Blood. 2025 Oct 7:blood.2024027009. doi: 10.1182/blood.2024027009.
PubMed Abstract available

RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
Blood. 2025;146:1664-1676.
PubMed Abstract available

September 2025

PENTER L, Maurer K, Cieri N, Lu W, et al
Mechanisms of immune escape and extramedullary tropism in leukemia cutis.
Blood. 2025 Sep 30:blood.2025029121. doi: 10.1182/blood.2025029121.
PubMed Abstract available

NEDUMANNIL R, Ashby M, Rowland J, Malherbe JAJ, et al
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.
Blood. 2025;146:1625-1629.
PubMed Abstract available

DEREVYANKO PK, Swart LE, Mata Casimiro LD, van Oort A, et al
Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia.
Blood. 2025 Sep 24:blood.2025028988. doi: 10.1182/blood.2025028988.
PubMed Abstract available

MATEOS-JAIMEZ J, Vidal Crespo A, Charalampopoulou S, Fernandez Perez R, et al
INCREASED LEF1 PROTEIN LEVELS AND ISOFORM SWITCHING DRIVE CELL PROLIFERATION IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Blood. 2025 Sep 22:blood.2025030129. doi: 10.1182/blood.2025030129.
PubMed Abstract available

NEVEN Q, Arfeuille C, Caye-Eude A, Durand P, et al
The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.
Blood. 2025 Sep 19:blood.2025029916. doi: 10.1182/blood.2025029916.
PubMed Abstract available

ANDRICOVICH J, Lap CJ, Tzatsos A
Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.
Blood. 2025;146:1493-1510.
PubMed Abstract available

SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Blood. 2025;146:1276-1285.
PubMed Abstract available

MARTINEZ TC, Jotte MRM, Khan S, Stoddart A, et al
CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.
Blood. 2025 Sep 8:blood.2024026815. doi: 10.1182/blood.2024026815.
PubMed Abstract available

VENKATESH H, Granados Centeno E, Luo Q, Arroyo M, et al
Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.
Blood. 2025 Sep 4:blood.2024028194. doi: 10.1182/blood.2024028194.
PubMed Abstract available

PAPAPETROU EP
Breaking ribosomes to fight leukemia.
Blood. 2025;146:1155-1156.
PubMed

DAMASKOU A, Wilson R, Gozdecka M, Giotopoulos G, et al
Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.
Blood. 2025;146:1239-1252.
PubMed Abstract available

GHOBADI A, Aldoss I, Maude SL, Bhojwani D, et al
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.
Blood. 2025;146:1163-1173.
PubMed Abstract available

REN H, Elliott N, Lye B, Sharif Shohan MU, et al
Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.
Blood. 2025 Sep 3:blood.2025029302. doi: 10.1182/blood.2025029302.
PubMed Abstract available

August 2025

CRISPINO JD
Meddling with METTL3 in acute megakaryoblastic leukemia.
Blood. 2025;146:1035-1036.
PubMed

GEYER MB, DeWolf S, Mi X, Weis K, et al
CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia.
Blood. 2025 Aug 27:blood.2025029532. doi: 10.1182/blood.2025029532.
PubMed Abstract available

O'BRIEN C, Nursimulu N, Tyagi A, Culp-Hill R, et al
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.
Blood. 2025 Aug 26:blood.2025029132. doi: 10.1182/blood.2025029132.
PubMed Abstract available

CHENG W, Yi X, Wang Z, Li JF, et al
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Blood. 2025 Aug 19:blood.2024027692. doi: 10.1182/blood.2024027692.
PubMed Abstract available

MONTEFIORI LE, Iacobucci I, Gao Q, Moore J, et al
Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.
Blood. 2025 Aug 14:blood.2025028985. doi: 10.1182/blood.2025028985.
PubMed Abstract available

ZHOU X, Chen J, Tang YL, Sun H, et al
Epidemiology, Clinical Features, and Molecular Basis of TTMV::RARA-driven Acute Promyelocytic Leukemia.
Blood. 2025 Aug 14:blood.2025028674. doi: 10.1182/blood.2025028674.
PubMed Abstract available

ANNESLEY C, Seidel K, Wu Q, Summers C, et al
Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL.
Blood. 2025;146:789-801.
PubMed Abstract available

CHEN S, Xiao Z
Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A::MLLT3 and U2AF1 mutation.
Blood. 2025;146:765.
PubMed

ABRUZZESE E, Chelysheva E
How I Manage Chronic Myeloid Leukemia During Pregnancy.
Blood. 2025 Aug 4:blood.2024026513. doi: 10.1182/blood.2024026513.
PubMed Abstract available

PAULI C, Kienhofer M, Blank MF, Begik O, et al
Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.
Blood. 2025 Aug 1:blood.2024027822. doi: 10.1182/blood.2024027822.
PubMed Abstract available

July 2025

DAVER N, Vyas P, Huls G, Dohner H, et al
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.
Blood. 2025;146:601-611.
PubMed Abstract available

SMITH A, Denny NDR, Chahrour C, Sharp K, et al
Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients.
Blood. 2025 Jul 29:blood.2024028019. doi: 10.1182/blood.2024028019.
PubMed Abstract available

UMEDA M, Hiltenbrand RL, Michmerhuizen NL, Barajas JM, et al
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia.
Blood. 2025 Jul 23:blood.2025028993. doi: 10.1182/blood.2025028993.
PubMed Abstract available

JI Y, Huang Y, Thomas T, Kapti EG, et al
CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis.
Blood. 2025 Jul 23:blood.2024026271. doi: 10.1182/blood.2024026271.
PubMed Abstract available

Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140(7):756-768.
Blood. 2025;146:397.
PubMed

CHENG J, Zhou J
Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?
Blood. 2025;146:396.
PubMed

KITTAI AS, Marchetti M, Al-Sawaf O, Benjamini O, et al
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
Blood. 2025;146:291-303.
PubMed Abstract available

WANG Z, Skwarska A, Poigaialwar G, Chaudhry S, et al
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
Blood. 2025;146:341-355.
PubMed Abstract available

GOEL P, Aryal S, Franceski AM, Kuznetsova V, et al
The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFkappaB signaling.
Blood. 2025 Jul 15:blood.2024028199. doi: 10.1182/blood.2024028199.
PubMed Abstract available

GRAINGER BT, Thompson PA, Cheah CY
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia.
Blood. 2025;146:145-154.
PubMed Abstract available

CARTER BZ, Mak PY, Ayoub E, Wu X, et al
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
Blood. 2025 Jul 3:blood.2025028935. doi: 10.1182/blood.2025028935.
PubMed Abstract available

MOHAMED A, Richardson AI
Therapy-related juvenile myelomonocytic leukemia.
Blood. 2025;146:127.
PubMed

June 2025

DEB PQ, Zhang X
B-lymphoblastic leukemia with KMT2A rearrangement with mature B-cell phenotype and surface lambda light-chain restriction.
Blood. 2025;145:3194.
PubMed

REVILLE PK, Wang B, Marvin-Peek J, Yuan B, et al
Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.
Blood. 2025;145:3015-3029.
PubMed Abstract available

LUGER SM
Introduction to a Blood Spotlight series on acute myeloid leukemia.
Blood. 2025;145:2801-2802.
PubMed

SELVARAJAH S, Xia D
A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
Blood. 2025;145:2931.
PubMed

COURTOIS L, Pinton A, Cabannes-Hamy A, Simonin M, et al
Surface pTalpha expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL.
Blood. 2025;145:2903-2913.
PubMed Abstract available

PERL AE
Approaching a therapeutic inflection point for FLT3-mutated AML.
Blood. 2025;145:2834-2839.
PubMed Abstract available

CHEN C, Xu J, Sussman JH, Vincent T, et al
Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome.
Blood. 2025;145:2685-2700.
PubMed Abstract available

KATER AP, Harrup R, Kipps TJ, Eichhorst B, et al
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Blood. 2025;145:2733-2745.
PubMed Abstract available

WIERDA WG, Eichhorst BF, Hallek MJ
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia.
Blood. 2025 Jun 2:blood.2025028570. doi: 10.1182/blood.2025028570.
PubMed Abstract available

May 2025

LU J, Xue SL, Wang Y, He XF, et al
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.
Blood. 2025;145:2645-2655.
PubMed Abstract available

EGAN G, Tasian SK
Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements.
Blood. 2025;145:2574-2586.
PubMed Abstract available

ESCHERICH CS, Li Z, Barnett KR, Li Y, et al
Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin.
Blood. 2025 May 28:blood.2024028215. doi: 10.1182/blood.2024028215.
PubMed Abstract available

MAYDAY MY, Biancon G, Wei M, Ramirez C, et al
RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation.
Blood. 2025 May 28:blood.2024027712. doi: 10.1182/blood.2024027712.
PubMed Abstract available

JUM'AH H, Viswanatha D
Classic hairy cell leukemia and concomitant smoldering myeloma.
Blood. 2025;145:2533.
PubMed

BASSAN R, Chiaretti S, Della Starza I, Santoro A, et al
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
Blood. 2025;145:2447-2459.
PubMed Abstract available

YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
PubMed Abstract available

WANG X, Yi H
Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
Blood. 2025;145:2396.
PubMed

SAORIN A, Dehler A, Galvan B, Steffen FD, et al
Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia.
Blood. 2025 May 13:blood.2025028938. doi: 10.1182/blood.2025028938.
PubMed Abstract available

PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
PubMed Abstract available

ALDOSS I, Clark MC, Forman SJ
How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapy.
Blood. 2025 May 12:blood.2024027267. doi: 10.1182/blood.2024027267.
PubMed Abstract available

CHALANDON Y, Simonetta F, Masouridi-Levrat S
How I approach hematopoietic stem cell transplantation for CML in a TKI world.
Blood. 2025 May 12:blood.2024026512. doi: 10.1182/blood.2024026512.
PubMed Abstract available

HOURIGAN CS
From prognostication to precision in acute myeloid leukemia.
Blood. 2025;145:2105-2106.
PubMed

Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577-589.
Blood. 2025;145:2231.
PubMed

LEVIS MJ, Hamadani M, Logan BR, Jones RJ, et al
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Blood. 2025;145:2138-2148.
PubMed Abstract available

GOOPTU M, Murdock HM, Soiffer RJ
How I treat AML relapse after allogeneic HSCT.
Blood. 2025;145:2128-2137.
PubMed Abstract available

TEFFERI A, Fathima S, Abdelmagid M, Alsugair A, et al
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia.
Blood. 2025 May 7:blood.2024027170. doi: 10.1182/blood.2024027170.
PubMed Abstract available

ARELLANO ML, Thirman MJ, DiPersio JF, Heiblig M, et al
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Blood. 2025 May 7:blood.2025028357. doi: 10.1182/blood.2025028357.
PubMed Abstract available

BULLINGER L
Mixed-phenotype acute leukemia revisited: omics lead the way.
Blood. 2025;145:1969-1971.
PubMed

April 2025

MCMAHON CM
Beyond conVENtional 7+3 in acute myeloid leukemia.
Blood. 2025;145:1831-1832.
PubMed

GARCIAZ S
STINGing leukemia stem cells through PSTK inhibition.
Blood. 2025;145:1833-1835.
PubMed

ZHANG W, Cai J, Wang X, Ma Y, et al
Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL.
Blood. 2025;145:1890-1902.
PubMed Abstract available

PODVIN B, Hardeman A
Early T-precursor acute lymphoblastic leukemia with mature plasmacytoid dendritic cell proliferation.
Blood. 2025;145:1827.
PubMed

CHAKRABORTY SR, Karrs JX
A rare case of nodal hairy cell leukemia exhibiting characteristic morphological and immunohistochemical features.
Blood. 2025;145:1826.
PubMed

DE KESEL J, Fijalkowski I, Pieters T, Borin C, et al
HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia.
Blood. 2025 Apr 15:blood.2024026848. doi: 10.1182/blood.2024026848.
PubMed Abstract available

DAVIDS MS, Kenderian SS, Flinn IW, Hill BT, et al
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
Blood. 2025 Apr 10:blood.2024027460. doi: 10.1182/blood.2024027460.
PubMed Abstract available

TURHAN AG
SMAC mimetics in action in chronic myeloid leukemia.
Blood. 2025;145:1596-1597.
PubMed

Zhu H-H, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597-605.
Blood. 2025;145:1703-1705.
PubMed

SILBERT SK, Rankin AW, Hoang CN, Semchenkova A, et al
Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.
Blood. 2025 Apr 7:blood.2024026655. doi: 10.1182/blood.2024026655.
PubMed Abstract available

DOMBRET H
Introduction to a review series on acute lymphoblastic leukemia.
Blood. 2025;145:1439.
PubMed

RAMPOTAS A, Roddie C
The present and future of CAR T-cell therapy for adult B-cell ALL.
Blood. 2025;145:1485-1497.
PubMed Abstract available

March 2025

BAKHSHI TJ, Pina-Oviedo S
Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
Blood. 2025;145:1437.
PubMed

CALO-PEREZ A, Martinez-Fernandez R
Atypical chronic myeloid leukemia: from cytology to molecular characterization.
Blood. 2025;145:1438.
PubMed

ROTHFUSS C, Baumann T, Donakonda S, Brauchle B, et al
Two-layered immune escape in AML is overcome by Fcgamma receptor activation and inhibition of PGE2 signaling in NK cells.
Blood. 2025;145:1395-1406.
PubMed Abstract available

HAN Q, Gu Y, Xiang H, Zhang L, et al
Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL.
Blood. 2025;145:1407-1421.
PubMed Abstract available

CHEN J, Suttorp M, Hijiya N
How I treat chronic myeloid leukemia in children and adolescents.
Blood. 2025 Mar 25:blood.2024026514. doi: 10.1182/blood.2024026514.
PubMed Abstract available

KOTROVA M, Proske C, Darzentas N, Laqua A, et al
NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.
Blood. 2025 Mar 25:blood.2024027175. doi: 10.1182/blood.2024027175.
PubMed Abstract available

LUGER SM
Introduction to a How I Treat series on acute myeloid leukemia.
Blood. 2025;145:1227-1228.
PubMed

FURSTENAU M, Robrecht S, Schneider C, Tausch E, et al
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
Blood. 2025;145:1282-1292.
PubMed Abstract available

WEI AH, Loo S, Daver N
How I treat patients with AML using azacitidine and venetoclax.
Blood. 2025;145:1237-1250.
PubMed Abstract available

LUO Q, Fortune AL, Lane AA
PI3Kgamma in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.
Blood. 2025 Mar 19:blood.2024027376. doi: 10.1182/blood.2024027376.
PubMed Abstract available

XU J, Sussman JH, Yang A, Yoshimura S, et al
STAT1-mediated interferon signatures associate with preclinical JAK-inhibitor sensitivity in T-cell acute lymphoblastic leukemia.
Blood. 2025 Mar 18:blood.2025028566. doi: 10.1182/blood.2025028566.
PubMed Abstract available

DALGETTY M, Cortes J
Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?
Blood. 2025 Mar 18:blood.2024027944. doi: 10.1182/blood.2024027944.
PubMed Abstract available

FALGAS A, Lazaro-Gorines R, Zanetti SR, Rubio-Perez L, et al
A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.
Blood. 2025 Mar 16:blood.2024025440. doi: 10.1182/blood.2024025440.
PubMed Abstract available

WANG WJ, Loghavi S
Acute myeloid leukemia with RUNX1::CBFA2T3 fusion.
Blood. 2025;145:1226.
PubMed

WULIJI N, Jones SMW, Gooley TA, Gerds AT, et al
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
Blood. 2025 Mar 11:blood.2024027543. doi: 10.1182/blood.2024027543.
PubMed Abstract available

TAM CS, Balendran S, Blombery P
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.
Blood. 2025;145:1005-1009.
PubMed Abstract available

February 2025

ZEIDNER JF, Sallman DA, Recher C, Daver NG, et al
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Blood. 2025 Feb 26:blood.2024027408. doi: 10.1182/blood.2024027408.
PubMed Abstract available

TAMIRO F, Padovano C, De Santis E, Di Iasio S, et al
NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia maintenance.
Blood. 2025 Feb 26:blood.2024027020. doi: 10.1182/blood.2024027020.
PubMed Abstract available

CONDOLUCI A, Romano I, Dietrich D, Pini K, et al
Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17.
Blood. 2025 Feb 26:blood.2024026879. doi: 10.1182/blood.2024026879.
PubMed Abstract available

ALLEN B, Bottomly D, Kohnke T, Wang A, et al
A CEBPB/IL-1beta/TNF-alpha Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia.
Blood. 2025 Feb 26:blood.2024028239. doi: 10.1182/blood.2024028239.
PubMed Abstract available

LINDER A, Nixdorf D, Kuhl N, Piseddu I, et al
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia.
Blood. 2025 Feb 26:blood.2024026934. doi: 10.1182/blood.2024026934.
PubMed Abstract available

AL JABRI M, Chang H
Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
Blood. 2025;145:897.
PubMed

PARISI X, Loghavi S
Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype.
Blood. 2025;145:784.
PubMed

SHAH V, Giotopoulos G, Osaki H, Meyerhofer M, et al
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.
Blood. 2025;145:748-764.
PubMed Abstract available

SILVA HJ, Martin G, Birocchi F, Wehrli M, et al
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.
Blood. 2025;145:720-731.
PubMed Abstract available

MANTZARIS I, Goldfinger M, Uriel M, Shastri A, et al
Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
Blood. 2025 Feb 7:blood.2024026700. doi: 10.1182/blood.2024026700.
PubMed Abstract available

SHEN Q, Hu S
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
Blood. 2025;145:652.
PubMed

FISKUS W, Mill CP, Bose P, Masarova L, et al
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
Blood. 2025;145:612-624.
PubMed Abstract available

HE L, Zhao T, Leong WZ, Sharda A, et al
PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells.
Blood. 2025 Feb 5:blood.2024026040. doi: 10.1182/blood.2024026040.
PubMed Abstract available

January 2025

LYAPICHEV KA, Behdad A
c-MYC stain as a potential minimal residual disease marker for acute myeloid leukemia with NPM1 mutation.
Blood. 2025;145:547.
PubMed

POHLY MF, Putzker K, Scheinost S, Ben Taarit L, et al
IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening.
Blood. 2025 Jan 27:blood.2024027171. doi: 10.1182/blood.2024027171.
PubMed Abstract available

ABEDIN SM, Uy GL, Michaelis LC
The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment.
Blood. 2025 Jan 24:blood.2024026004. doi: 10.1182/blood.2024026004.
PubMed Abstract available

CHAPAPRIETA V, Maiques-Diaz A, Nadeu F, Clot G, et al
Dual Biological Role and Clinical Impact of De Novo Chromatin Activation in Chronic Lymphocytic Leukemia.
Blood. 2025 Jan 22:blood.2024025396. doi: 10.1182/blood.2024025396.
PubMed Abstract available

ALIKARAMI F, Xie HM, Riedel SS, Goodrow H, et al
GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.
Blood. 2025 Jan 22:blood.2024025761. doi: 10.1182/blood.2024025761.
PubMed Abstract available

LYU J, Liu Y, Liu N, Vu H, et al
CD44-Mediated Metabolic Rewiring is A Targetable Dependency of IDH-Mutant Leukemia.
Blood. 2025 Jan 22:blood.2024027207. doi: 10.1182/blood.2024027207.
PubMed Abstract available

SCHAFER HACKENHAAR F, Refhagen N, Hagleitner MM, van Leeuwen FN, et al
CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia.
Blood. 2025 Jan 22:blood.2024026027. doi: 10.1182/blood.2024026027.
PubMed Abstract available

ARAUJO JL, Wagenblast E, Voisin V, McLeod J, et al
FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells.
Blood. 2025 Jan 22:blood.2024025886. doi: 10.1182/blood.2024025886.
PubMed Abstract available

GALERA P, Dilip D, Derkach A, Chan A, et al
Defining 2 Biologically and Clinically Distinct Groups in Acute Leukemia with a Mixed Phenotype.
Blood. 2025 Jan 15:blood.2024026273. doi: 10.1182/blood.2024026273.
PubMed Abstract available

RONNACKER J, Grau M, Klasmeier M, Klesse C, et al
Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia.
Blood. 2025 Jan 15:blood.2024026886. doi: 10.1182/blood.2024026886.
PubMed Abstract available

NYGREN PJ, Bouhlal JOV, Jokinen E, Forsten S, et al
High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia.
Blood. 2025 Jan 10:blood.2024025286. doi: 10.1182/blood.2024025286.
PubMed Abstract available

PURVIS K, Zhou Y, Karol SE, Rubnitz JE, et al
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
Blood. 2025;145:190-201.
PubMed Abstract available

DING YY, Sussman JH, Madden K, Loftus JP, et al
Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
Blood. 2025 Jan 7:blood.2024026482. doi: 10.1182/blood.2024026482.
PubMed Abstract available

BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
PubMed Abstract available

DOMBRET H
Introduction to a How I Treat series on acute lymphoblastic leukemia.
Blood. 2025;145:1-2.
PubMed

CHIARETTI S, Foa R
How I treat adult Ph+ ALL.
Blood. 2025;145:11-19.
PubMed Abstract available

LAMBLE AJ, Kovach AE, Shah NN
How I treat postimmunotherapy relapsed B-ALL.
Blood. 2025;145:64-74.
PubMed Abstract available

December 2024

PASSET M, Kim R, Clappier E
Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.
Blood. 2024 Dec 30:blood.2023022919. doi: 10.1182/blood.2023022919.
PubMed Abstract available

CRUZ-RODRIGUEZ N, Deininger MW
Novel Treatment Strategies for Chronic Myeloid Leukemia.
Blood. 2024 Dec 27:blood.2024026312. doi: 10.1182/blood.2024026312.
PubMed Abstract available

ESCHERICH CS, Moriyama T, Li Z, Hsiao Y, et al
DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
Blood. 2024 Dec 27:blood.2024026085. doi: 10.1182/blood.2024026085.
PubMed Abstract available

MILLMAN SE, Chaves-Perez A, Janaki-Raman S, Ho YJ, et al
alpha-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia.
Blood. 2024 Dec 27:blood.2024025245. doi: 10.1182/blood.2024025245.
PubMed Abstract available

NAHARRO EF, Linden MA
Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
Blood. 2024;144:2793.
PubMed

LACHOWIEZ CA, Ravikumar VI, Othman J, O'Nions J, et al
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
Blood. 2024;144:2788-2792.
PubMed Abstract available

BROWN JR, Eichhorst B, Lamanna N, O'Brien SM, et al
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
Blood. 2024;144:2706-2717.
PubMed Abstract available

HULS GA, Woolthuis CM, Schuringa JJ
Menin inhibitors in the treatment of acute myeloid leukemia.
Blood. 2024 Dec 24:blood.2024026232. doi: 10.1182/blood.2024026232.
PubMed Abstract available

ARONS E, Tai CH, Suraj J, Liu Y, et al
Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia.
Blood. 2024 Dec 24:blood.2024026894. doi: 10.1182/blood.2024026894.
PubMed Abstract available

CUI B, Ai L, Lei M, Duan Y, et al
Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia.
Blood. 2024 Dec 11:blood.2024025618. doi: 10.1182/blood.2024025618.
PubMed Abstract available

BOUDIA F, Baille M, Babin L, Aid Z, et al
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation.
Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505.
PubMed Abstract available

HAUBNER S, Subklewe M, Sadelain M
Honing CAR T cells to tackle acute myeloid leukemia.
Blood. 2024 Dec 4:blood.2024024063. doi: 10.1182/blood.2024024063.
PubMed Abstract available

November 2024

GOLDFINGER M, Mantzaris I, Shastri A, Saunthararajah Y, et al
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
Blood. 2024;144:2360-2363.
PubMed Abstract available

DOHNER H, DiNardo CD, Appelbaum FR, Craddock C, et al
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Blood. 2024;144:2169-2173.
PubMed Abstract available

DOHNER H, Pratz KW, DiNardo CD, Wei AH, et al
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
Blood. 2024;144:2211-2222.
PubMed Abstract available

MA J, Wang Z, Mintzlaff D, Zhang H, et al
Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia.
Blood. 2024 Nov 19:blood.2024025277. doi: 10.1182/blood.2024025277.
PubMed Abstract available

NAIR MS, Silbert SK, Rejeski K, Wilson KA, et al
Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
Blood. 2024 Nov 19:blood.2024025910. doi: 10.1182/blood.2024025910.
PubMed Abstract available

LU P, Zhang X, Yang J, Li J, et al
Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia.
Blood. 2024 Nov 19:blood.2024024861. doi: 10.1182/blood.2024024861.
PubMed Abstract available

Handa S, Lee J-O, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022;140(25):2663-2671.
Blood. 2024;144:2068.
PubMed

CHEVALIER S, Legrand C
B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
Blood. 2024;144:2067.
PubMed

HUNTER AM, Patnaik MM, Itzykson R, Mesa R, et al
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Blood. 2024;144:1987-1992.
PubMed Abstract available

LOPEZ-MILLAN B, Rubio-Gayarre A, Vinyoles M, Trincado JL, et al
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.
Blood. 2024;144:2002-2017.
PubMed Abstract available

VOSO MT, Guarnera L, Lehmann S, Dohner K, et al
Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
Blood. 2024 Nov 6:blood.2024026186. doi: 10.1182/blood.2024026186.
PubMed Abstract available

GUILHOT F, Hehlmann R
Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.
Blood. 2024 Nov 1:blood.2024026311. doi: 10.1182/blood.2024026311.
PubMed Abstract available

October 2024

LUO MX, Tan T, Trussart M, Poch A, et al
Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia.
Blood. 2024 Oct 29:blood.2024024341. doi: 10.1182/blood.2024024341.
PubMed Abstract available

WU Q, Chen D
Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus.
Blood. 2024;144:1846.
PubMed

KIM E, Chen SS, Sivina M, Hwang H, et al
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.
Blood. 2024 Oct 23:blood.2024025683. doi: 10.1182/blood.2024025683.
PubMed Abstract available

LIU Y, Bollino DR, Bah OM, Strovel ET, et al
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia.
Blood. 2024 Oct 22:blood.2024024837. doi: 10.1182/blood.2024024837.
PubMed Abstract available

GOKBUGET N, Steffen B
How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia.
Blood. 2024 Oct 11:blood.2023023156. doi: 10.1182/blood.2023023156.
PubMed Abstract available

KWOK M, Stankovic T
Targeting therapeutic vulnerabilities in T-PLL.
Blood. 2024;144:1548-1550.
PubMed

NIEDER R, Li W
Constitutive STAT5 activation in precursor B-cell acute lymphoblastic leukemia with P2RY8::CRLF2 fusion.
Blood. 2024;144:1646.
PubMed

VON JAN J, Timonen S, Braun T, Jiang Q, et al
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.
Blood. 2024;144:1595-1610.
PubMed Abstract available

SIMONIN M, Vasseur L, Lengline E, Lhermitte L, et al
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
Blood. 2024;144:1570-1580.
PubMed Abstract available

NEWMAN H, Teachey DT
A T-ALL order: a new risk classifier for T-ALL.
Blood. 2024;144:1545-1547.
PubMed

ROBOZ GJ, Canaani J
How I use Maintenance Therapy in Acute Myeloid Leukemia.
Blood. 2024 Oct 7:blood.2024024010. doi: 10.1182/blood.2024024010.
PubMed Abstract available

LUSKIN MR, Murakami MA, Keating JH, Flamand Y, et al
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Blood. 2024 Oct 7:blood.2024025800. doi: 10.1182/blood.2024025800.
PubMed Abstract available

ZHOU X, Chen X, Chen J, Wen L, et al
Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL.
Blood. 2024;144:1471-1485.
PubMed Abstract available

POLONEN P, Mullighan CG, Teachey DT
Classification and risk stratification in T-lineage acute lymphoblastic leukemia.
Blood. 2024 Oct 2:blood.2023022920. doi: 10.1182/blood.2023022920.
PubMed Abstract available

KYTOLA S, Vanttinen IM, Ruokoranta T, Partanen A, et al
Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.
Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968.
PubMed Abstract available

GREEN SD, Wang ES
How I Treat: Secondary Acute Myeloid Leukemia.
Blood. 2024 Oct 2:blood.2024024011. doi: 10.1182/blood.2024024011.
PubMed Abstract available

September 2024

POCOCK R, Mansour MR
T-ALL and T-LBL: a notch apart.
Blood. 2024;144:1356-1357.
PubMed

LI Z, Meng G
Targeting DUX4-r leukemia via PI3K and CD371.
Blood. 2024;144:1354-1356.
PubMed

SHARMAN JP
Pirtobrutinib combinations in CLL.
Blood. 2024;144:1351-1352.
PubMed

THORSSON H, Henningsson R, Puente-Moncada N, Pena-Martinez P, et al
Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases.
Blood. 2024;144:1399-1411.
PubMed Abstract available

ROEKER LE, Woyach JA, Cheah CY, Coombs CC, et al
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
Blood. 2024;144:1374-1386.
PubMed Abstract available

RAHMAN S, Bloye G, Farah N, Demeulemeester J, et al
Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.
Blood. 2024 Sep 24:blood.2024024300. doi: 10.1182/blood.2024024300.
PubMed Abstract available

JIN Q, Harris E, Myers JA, Mehmood R, et al
Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia.
Blood. 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281.
PubMed Abstract available

LOO S, Potter N, Ivey A, O'Nions J Dr, et al
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia.
Blood. 2024 Sep 24:blood.2024026605. doi: 10.1182/blood.2024026605.
PubMed Abstract available

WANG ES
Curing APL in Latin America: more than just ATRA.
Blood. 2024;144:1237-1238.
PubMed

BONADIES N
SHERLOCK unmasks fusion-driven leukemias.
Blood. 2024;144:1241-1243.
PubMed

VEDULA RS, Karp HQ, Koob J, Lim F, et al
CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias.
Blood. 2024;144:1290-1299.
PubMed Abstract available

PENTER L, Wu CJ
Therapy response in AML: a tale of two T cells.
Blood. 2024;144:1134-1136.
PubMed

KWON MC, Thuring JW, Querolle O, Dai X, et al
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
Blood. 2024;144:1206-1220.
PubMed Abstract available

WALTER RB, Potter V, Craddock C
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old.
Blood. 2024 Sep 6:blood.2024024247. doi: 10.1182/blood.2024024247.
PubMed Abstract available

BADAR T, Luger SM, Litzow MR
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.
Blood. 2024 Sep 5:blood.2023022921. doi: 10.1182/blood.2023022921.
PubMed Abstract available

SALLMAN DA, Stahl M
TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
Blood. 2024 Sep 5:blood.2024024245. doi: 10.1182/blood.2024024245.
PubMed Abstract available

FALKENBURG JHF, Heemskerk MHM
TCR targeting hematopoiesis to cure leukemia.
Blood. 2024;144:1031-1033.
PubMed

August 2024

SUMMERS RJ, Teachey DT
SNPing away poor outcomes in T-ALL.
Blood. 2024;144:924-925.
PubMed

EADIE LN, Lagonik E, Page EC, Schutz CE, et al
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.
Blood. 2024;144:1022-1026.
PubMed

BALDUCCI E, Simonin M, Duployez N, Steimle T, et al
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
Blood. 2024;144:988-1000.
PubMed Abstract available

WADHWA A, Chen Y, Hageman L, Angiolillo A, et al
Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia: A COG-AALL03N1 Report.
Blood. 2024 Aug 27:blood.2024024455. doi: 10.1182/blood.2024024455.
PubMed Abstract available

COBALEDA C, Sanchez-Garcia I
Childhood leukemia prevention within reach.
Blood. 2024;144:799-800.
PubMed

INGELFINGER F
Hijacking T helper cells for AML progression.
Blood. 2024;144:804-805.
PubMed

XU Z, Padmore R
AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte arrest.
Blood. 2024;144:918.
PubMed

BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
PubMed Abstract available

ZHOU X, Zhang L, Aryal S, Veasey V, et al
Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia.
Blood. 2024 Aug 16:blood.2023023644. doi: 10.1182/blood.2023023644.
PubMed Abstract available

HU Z, Ok CY
Immature erythroblasts in pleural effusion: an initial presentation of acute erythroid leukemia in a patient with a history of MDS.
Blood. 2024;144:794.
PubMed

ITZYKSON R
NPM1-mutated AML: how many diseases?
Blood. 2024;144:681-683.
PubMed

OTHMAN J, Potter N, Ivey A, Tazi Y, et al
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Blood. 2024;144:714-728.
PubMed Abstract available

LEYTE-VIDAL A, Garrido Ruiz D, DeFilippis R, Leske IB, et al
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
Blood. 2024;144:639-645.
PubMed Abstract available

YEUNG DT, Shanmuganathan N, Reynolds J, Branford S, et al
Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
Blood. 2024 Aug 5:blood.2024024657. doi: 10.1182/blood.2024024657.
PubMed Abstract available

ARRIETA-BOLANOS E, van der Burg LLJ, Gedde-Dahl T, Robin M, et al
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Blood. 2024 Aug 5:blood.2024024351. doi: 10.1182/blood.2024024351.
PubMed Abstract available

Metzeler KH, Herold T, Rothenberg-Turley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686-698.
Blood. 2024;144:589.
PubMed

MOSS P
A tumor suppressor of CLL: all (T-)bets are on.
Blood. 2024;144:467-469.
PubMed

COOK JA, Lott L, Perry J, Eckel AM, et al
Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML.
Blood. 2024;144:581-585.
PubMed Abstract available

EFFICACE F, Kicinski M, Coens C, Suciu S, et al
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
Blood. 2024;144:541-551.
PubMed Abstract available

July 2024

ZHANG X, Liu B, Huang J, Zhang YL, et al
A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
Blood. 2024 Jul 24:blood.2024024761. doi: 10.1182/blood.2024024761.
PubMed Abstract available

TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
PubMed Abstract available

van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142.
Blood. 2024;144:341.
PubMed

Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
Blood. 2024;144:342.
PubMed

RADICH J
Transplant, MRD, and predicting relapse in AML.
Blood. 2024;144:245-247.
PubMed

OPAT S
Treatment of relapsed CLL "in the BAAG"?
Blood. 2024;144:243-244.
PubMed

MUFFLY L, Liang EC, Dolan JG, Pulsipher MA, et al
How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
Blood. 2024;144:253-261.
PubMed Abstract available

FURSTENAU M, Giza A, Weiss J, Kleinert F, et al
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood. 2024;144:272-282.
PubMed Abstract available

WEI Q, Xu J
Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.
Blood. 2024;144:238.
PubMed

HOURIGAN CS
How complete must an AML remission be?
Blood. 2024;144:131-132.
PubMed

AL-SAWAF O, Robrecht S, Zhang C, Olivieri S, et al
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study.
Blood. 2024 Jul 10:blood.2024024631. doi: 10.1182/blood.2024024631.
PubMed Abstract available

ISSA GC, Stein EM, DiNardo CDD
How I Treat: Differentiation Therapy in Acute Myeloid Leukemia.
Blood. 2024 Jul 8:blood.2024024008. doi: 10.1182/blood.2024024008.
PubMed Abstract available

SUO S, Zhao D, Li F, Zhang Y, et al
Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects in T-Cell Acute Lymphoblastic Leukemia.
Blood. 2024 Jul 5:blood.2023023400. doi: 10.1182/blood.2023023400.
PubMed Abstract available

SRINAGESH HK, Jackson C, Shiraz P, Jeyakumar N, et al
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
Blood. 2024 Jul 5:blood.2024024952. doi: 10.1182/blood.2024024952.
PubMed Abstract available

LUM SH, Eikema DJ, Piepenbroek B, Wynn R, et al
Outcome of Hematopoietic Stem Cell Transplantation in 813 Pediatric Patients with Fanconi Anemia.
Blood. 2024 Jul 5:blood.2023022751. doi: 10.1182/blood.2023022751.
PubMed Abstract available

QIAN Z, Yu F
GADD45A: a key tumor suppressor in AML subtypes.
Blood. 2024;144:6-7.
PubMed

ZHAO Y, Short NJ, Kantarjian HM, Chang TC, et al
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood. 2024;144:61-73.
PubMed Abstract available

June 2024

RADPOUR R, Simillion C, Wang B, Abbas HA, et al
IL-9 Secreted by Leukemia Stem Cells Induces Th1-Skewed CD4+ T-Cells, which Promote Their Expansion.
Blood. 2024 Jun 28:blood.2024024000. doi: 10.1182/blood.2024024000.
PubMed Abstract available

BIDOT S, Feldman AL
Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Blood. 2024;143:2808.
PubMed

LENK L, Baccelli I, Laqua A, Heymann J, et al
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
Blood. 2024;143:2735-2748.
PubMed Abstract available

LIN HY, Mohammadhosseini M, McClatchy J, Villamor-Paya M, et al
The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1beta-mediated AML progression.
Blood. 2024;143:2749-2762.
PubMed Abstract available

WALCZAK P, Fodil S, Vignal N, Cabannes-Hamy A, et al
Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia.
Blood. 2024 Jun 25:blood.2024024838. doi: 10.1182/blood.2024024838.
PubMed Abstract available

BARTRAM J, Ancliff P, Vora A
How I Treat on Infant Acute Lymphoblastic Leukemia.
Blood. 2024 Jun 21:blood.2023023154. doi: 10.1182/blood.2023023154.
PubMed Abstract available

Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]
Blood. 2024;143:2676.
PubMed

FORCONI F
Time for a new prognostic score in CLL?
Blood. 2024;143:2561-2562.
PubMed

GAO Q, Harrison CJ
B-ALL with intrachromosomal amplification of chromosome 21 in a carrier of the Robertsonian translocation rob(14;21)c.
Blood. 2024;143:2672.
PubMed

SATO T, Yoshida K, Toki T, Kanezaki R, et al
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
Blood. 2024;143:2627-2643.
PubMed Abstract available

FARROKHI A, Atre T, Salitra S, Aletaha M, et al
Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic leukemia.
Blood. 2024 Jun 14:blood.2024025038. doi: 10.1182/blood.2024025038.
PubMed Abstract available

SANZ J, Labopin M, Choi G, Kulagin A, et al
Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT.
Blood. 2024;143:2534-2543.
PubMed Abstract available

MARCHAND T, Lamy de La Chapelle T, Loughran TP
A modern view of LGL leukemia.
Blood. 2024 Jun 7:blood.2023021790. doi: 10.1182/blood.2023021790.
PubMed Abstract available

LUSKIN MR
Finding the perPh+ect balance in Ph+ ALL.
Blood. 2024;143:2339-2340.
PubMed

May 2024

KANG YA
Awakening your innate power to combat AML.
Blood. 2024;143:2223-2224.
PubMed

HALL T, Gurbuxani S, Crispino JD
Malignant progression of preleukemic disorders.
Blood. 2024;143:2245-2255.
PubMed Abstract available

ONIDA F, Gagelmann N, Chalandon Y, Kobbe G, et al
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Blood. 2024;143:2227-2244.
PubMed Abstract available

KOURY LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, et al
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890.
PubMed Abstract available

BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
PubMed Abstract available

SAWYER EM, Kraft AS
SMACing down relapsed T-ALL.
Blood. 2024;143:2116-2117.
PubMed

MAZZIOTTA F, Biavati L, Rimando JC, Rutella S, et al
CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia.
Blood. 2024 May 22:blood.2023021680. doi: 10.1182/blood.2023021680.
PubMed Abstract available

LEWIS RI, Vom Stein AF, Hallek MJ
Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.
Blood. 2024 May 22:blood.2023022861. doi: 10.1182/blood.2023022861.
PubMed Abstract available

WOYACH JA, Jones D, Jurczak W, Robak T Prof, et al
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659.
PubMed Abstract available

MRD and EFS in pediatric T-lymphoblastic lymphoma.
Blood. 2024;143:2111.
PubMed

Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
Blood. 2024;143:2108-2110.
PubMed

RIBERA JM
MRD: also for T-lymphoblastic lymphoma.
Blood. 2024;143:2017-2019.
PubMed

TAMENI A, Toffalori C, Vago L
Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant.
Blood. 2024 May 10:blood.2023019962. doi: 10.1182/blood.2023019962.
PubMed Abstract available

LE RQ, Przepiorka D, Chen H, Shen YL, et al
Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
Blood. 2024 May 10:blood.2023023313. doi: 10.1182/blood.2023023313.
PubMed Abstract available

RECHER C
Transplant in AML: just follow the NPM1 guide!
Blood. 2024;143:1881-1882.
PubMed

SUNG PJ
PIKing the right target in AML.
Blood. 2024;143:1884-1885.
PubMed

OTHMAN J, Potter N, Ivey A, Jovanovic J, et al
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Blood. 2024;143:1931-1936.
PubMed Abstract available

GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
Blood. 2024;143:1903-1930.
PubMed Abstract available

GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
Blood. 2024;143:1891-1902.
PubMed Abstract available

April 2024

ROESSNER PM, Seufert I, Chapaprieta V, Jayabalan R, et al
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
Blood. 2024 Apr 29:blood.2023021990. doi: 10.1182/blood.2023021990.
PubMed Abstract available

KRAKOW EF, Brault M, Summers C, Cunningham TM, et al
HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105.
PubMed Abstract available

WIENECKE CP, Heida B, Venturini L, Gabdoulline R, et al
Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
Blood. 2024 Apr 26:blood.2023022697. doi: 10.1182/blood.2023022697.
PubMed Abstract available

SUBKLEWE M
T cells take aim in AML: targeting IDH2.
Blood. 2024;143:1681-1682.
PubMed

ABDELBAKY SB, Giacopelli B, Rabe KG, Yamaguchi K, et al
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
Blood. 2024;143:1752-1757.
PubMed Abstract available

TRAN TH, Tasian SK
How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults.
Blood. 2024 Apr 24:blood.2023023153. doi: 10.1182/blood.2023023153.
PubMed Abstract available

LAMBLE AJ, Rau RE
IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
Blood. 2024;143:1556-1557.
PubMed

CUNEO A, Ghia P
Ibrutinib in CLL: benefit for all?
Blood. 2024;143:1558-1559.
PubMed

BUFFET R
How lipid coating soothes the gut in AML therapy.
Blood. 2024;143:1559-1561.
PubMed

RENGA G, Nunzi E, Stincardini C, Pariano M, et al
CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
Blood. 2024;143:1628-1645.
PubMed Abstract available

WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood. 2024;143:1616-1627.
PubMed Abstract available

LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
PubMed Abstract available

BULLINGER L, Kronke J
Making AML fly too close to the sun.
Blood. 2024;143:1438-1439.
PubMed

BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Blood. 2024;143:1513-1527.
PubMed Abstract available

KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
PubMed Abstract available

HASSAN N, Yi H, Malik B, Gaspard-Boulinc LC, et al
Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML.
Blood. 2024 Apr 5:blood.2024024072. doi: 10.1182/blood.2024024072.
PubMed Abstract available

MARCAIS A
Targeting PD-L1 to treat ATLL?
Blood. 2024;143:1320-1322.
PubMed

MINA A, Greenberg PL, Deeg HJ
How I reduce and treat posttransplant relapse of MDS.
Blood. 2024;143:1344-1354.
PubMed Abstract available

BASTIAN L, Beder T, Barz MJ, Bendig S, et al
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Blood. 2024;143:1391-1398.
PubMed Abstract available

March 2024

INESS AN, Bachireddy P
GPR56 in GVL: marker or mechanism?
Blood. 2024;143:1206-1207.
PubMed

MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
Blood. 2024;143:1269-1281.
PubMed Abstract available

BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Blood. 2024;143:1139-1156.
PubMed Abstract available

KLEIN K, Kollmann S, Hiesinger A, List J, et al
A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655.
PubMed Abstract available

AZOULAY E, Maertens J, Lemiale V
How I manage acute respiratory failure in patients with hematological malignancies.
Blood. 2024;143:971-982.
PubMed Abstract available

MACK EA, Dougher MC, Ginda AM, Cahill C, et al
Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
Blood. 2024;143:1049-1054.
PubMed Abstract available

FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al
Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640.
PubMed Abstract available

HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
PubMed Abstract available

CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502.
PubMed Abstract available

Colom Diaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023;142(6):533-542.
Blood. 2024;143:939.
PubMed

AHMED R, Feldman AL
Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
Blood. 2024;143:938.
PubMed

O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al
Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
Blood. 2024;143:933-937.
PubMed Abstract available

ESCHERICH CS, Chen W, Li Y, Yang W, et al
Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336.
PubMed Abstract available

AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al
Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell Acute Lymphoblastic Leukemia.
Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455.
PubMed Abstract available

February 2024

BARROS PINTO MP, Cabecadas J
Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
Blood. 2024;143:833.
PubMed

MURTADHA M, Park M, Zhu Y, Caserta E, et al
CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNgamma-induced CD38 expression.
Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570.
PubMed Abstract available

VAN OUTERSTERP I, Tasian SK, Reichert CE, Boeree A, et al
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain.
Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
PubMed Abstract available

BARBOSA K, Deshpande A, Perales M, Xiang P, et al
Transcriptional control of leukemogenesis by the chromatin reader SGF29.
Blood. 2024;143:697-712.
PubMed Abstract available

BISWAS J, Abdel-Wahab O
A new SAGA for AML: targeting SGF29 in AML.
Blood. 2024;143:657-658.
PubMed

SUMMERS RJ, Teachey DT, Hunger SP
How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in children.
Blood. 2024 Feb 16:blood.2023023155. doi: 10.1182/blood.2023023155.
PubMed Abstract available

MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al
CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992.
PubMed Abstract available

FISKUS W, Piel J, Collins MP, Hentemann M, et al
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832.
PubMed Abstract available

COTY-FATTAL Z, Richardson AI
A 3-year-old with chronic myeloid leukemia.
Blood. 2024;143:651.
PubMed

BARAJAS JM, Rasouli M, Umeda M, Hiltenbrand R, et al
Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
Blood. 2024;143:619-630.
PubMed Abstract available

BERNT KM
Menin dependence: UBTF-ITD AML joins the club.
Blood. 2024;143:567-569.
PubMed

CHEN B, Abdel-Wahab O
Targeting the cBAF complex in T-ALL.
Blood. 2024;143:566-567.
PubMed

ARBER C
Two to tango: engineered T cells against AML.
Blood. 2024;143:476-478.
PubMed

QIU L, Naresh KN
Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid.
Blood. 2024;143:561.
PubMed

DAO T, Xiong G, Mun SS, Meyerberg J, et al
A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
Blood. 2024;143:507-521.
PubMed Abstract available

BHATT VR, Uy GL, Klepin HD
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
Blood. 2024;143:483-487.
PubMed Abstract available

ROUSSELOT P
Old rivals become new friends.
Blood. 2024;143:380-382.
PubMed

ORDONEZ MAZARIEGOS EE, Dimopoulos YP
A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
Blood. 2024;143:473.
PubMed

January 2024

GU H, Chen C, Hou ZS, He XD, et al
PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202.
PubMed Abstract available

SCHRAW JM
Anticancer drug exposure in utero and leukemia.
Blood. 2024;143:293-294.
PubMed

BARATA JT
Darwin, MSI2, and relapse in T-ALL.
Blood. 2024;143:294-296.
PubMed

SAHASRABUDHE KD, Mims AS
MRD in AML: who, what, when, where, and how?
Blood. 2024;143:296-298.
PubMed

OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Blood. 2024;143:336-341.
PubMed Abstract available

LEUNG WK, Torres Chavez AG, French-Kim M, Shafer P, et al
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
Blood. 2024 Jan 19:blood.2023021979. doi: 10.1182/blood.2023021979.
PubMed Abstract available

WEINACHT KG
The rise of haplo: a quest for the perfect graft.
Blood. 2024;143:193-195.
PubMed

alphabetaT/CD19-depleted haploHSCT for pediatric leukemia.
Blood. 2024;143:291.
PubMed

CHEN H, Wang H
Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia.
Blood. 2024;143:290.
PubMed

SAULTIER P, Michel G
How I Treat: long-term survivors of childhood acute leukemia.
Blood. 2024 Jan 16:blood.2023019804. doi: 10.1182/blood.2023019804.
PubMed Abstract available

BULDINI B, Varotto E, Maurer-Granofszky M, Gaipa G, et al
CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952.
PubMed Abstract available

Bamezai S, Pulikkottil AJ, Yadav T, et al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90-105.
Blood. 2024;143:184.
PubMed

DIMOPOULOS YP, Loghavi S
Acute leukemia of ambiguous lineage with BCL11B rearrangement.
Blood. 2024;143:183.
PubMed

GHORASHIAN S, Lucchini G, Richardson R, Nguyen K, et al
CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
Blood. 2024;143:118-123.
PubMed Abstract available

VELTMAAT L, Cortes J
Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.
Blood. 2024 Jan 9:blood.2023022403. doi: 10.1182/blood.2023022403.
PubMed Abstract available

MOSS P
Ibrutinib reversal of immune exhaustion in CLL.
Blood. 2024;143:5-7.
PubMed

Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078.
Blood. 2024;143:93.
PubMed

PAPAZOGLOU D, Wang XV, Shanafelt TD, Lesnick CE, et al
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
Blood. 2024;143:57-63.
PubMed Abstract available

December 2023

QUESSADA J, Loosveld M
CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.
Blood. 2023;142:2332.
PubMed

HASSERJIAN RP, Germing U, Malcovati L
Diagnosis and classification of myelodysplastic syndromes.
Blood. 2023;142:2247-2257.
PubMed Abstract available

DEZERN AE, Greenberg PL
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
Blood. 2023;142:2258-2267.
PubMed Abstract available

CHIBA M, Shimono J, Suto K, Ishio T, et al
Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
PubMed Abstract available

BRECCIA M
A traffic light for TFR by lineage-specific MRD.
Blood. 2023;142:2129-2130.
PubMed

FU L, Gong S
KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
Blood. 2023;142:2220.
PubMed

NIH natural history study of FPDMM patients.
Blood. 2023;142:2222.
PubMed

FRANK D, Patnana PK, Vorwerk J, Mao L, et al
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Blood. 2023;142:2175-2191.
PubMed Abstract available

CUNNINGHAM L, Merguerian M, Calvo KR, Davis J, et al
Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Blood. 2023;142:2146-2158.
PubMed Abstract available

MARCELLINO BK
PPM1D inhibition may allow us to WIP leukemia.
Blood. 2023;142:2040-2042.
PubMed

COUSTAN-SMITH E, Conter V
Closing the circle for ETP ALL.
Blood. 2023;142:2039-2040.
PubMed

WOOD BL, Devidas M, Summers RJ, Chen Z, et al
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
Blood. 2023;142:2069-2078.
PubMed Abstract available

DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
PubMed Abstract available

PALM-APERGI C
PLK4, a potential target against AML.
Blood. 2023;142:1941-1942.
PubMed

STONE RM
FLT(3)-ing about: the search for the best inhibitor.
Blood. 2023;142:1937-1938.
PubMed

MAN CH, Lam W, Dang CC, Zeng XY, et al
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
Blood. 2023;142:2002-2015.
PubMed Abstract available

FLEMING S, Tsai XC, Morris R, Hou HA, et al
TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
Blood. 2023;142:2029-2033.
PubMed Abstract available

LOO S, Roberts AW, Anstee NS, Kennedy GA, et al
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood. 2023;142:1960-1971.
PubMed Abstract available

November 2023

BEWERSDORF JP, How J, Masarova L, Bose P, et al
Moving toward disease modification in polycythemia vera.
Blood. 2023;142:1859-1870.
PubMed Abstract available

DAVIDS MS
Functional cure reported in CLL.
Blood. 2023;142:1761-1763.
PubMed

LIN E, Chen W
Acute myeloid leukemia with NUP98::HOXA9 mimicking acute promyelocytic leukemia.
Blood. 2023;142:1845.
PubMed

Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754-2756.
Blood. 2023;142:1846-1847.
PubMed

THOMPSON PA, Bazinet A, Wierda WG, Tam CS, et al
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Blood. 2023;142:1784-1788.
PubMed Abstract available

KIM R, Bergugnat H, Pastoret C, Pasquier F, et al
Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Blood. 2023;142:1806-1817.
PubMed Abstract available

ROLLIG C
Gemtuzumab ozogamicin in AML: the next chapter.
Blood. 2023;142:1673-1674.
PubMed

STRASSER B, Haushofer A
Cabot rings in chronic myelomonocytic leukemia.
Blood. 2023;142:1757.
PubMed

FREEMAN SD, Thomas A, Thomas I, Hills RK, et al
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Blood. 2023;142:1697-1707.
PubMed Abstract available

Fractionated vs single-dose gemtuzumab for AML.
Blood. 2023;142:1759.
PubMed

BUENO C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, et al
A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
Blood. 2023;142:1752-1756.
PubMed Abstract available

THOL FR, Dohner H, Ganser A
How I treat refractory and relapsed acute myeloid leukemia.
Blood. 2023 Nov 9:blood.2023022481. doi: 10.1182/blood.2023022481.
PubMed Abstract available

VYAS P
Changing treatment changing prognosis of mutations.
Blood. 2023;142:1583-1585.
PubMed

AOKI K, Hyuga M, Tarumoto Y, Nishibuchi G, et al
Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
Blood. 2023 Nov 3:blood.2023020857. doi: 10.1182/blood.2023020857.
PubMed Abstract available

October 2023

JABBOUR EJ, Haddad FG, Short NJ, Senapati J, et al
Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission.
Blood. 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330.
PubMed Abstract available

MALAGA ML, Carrillo LF
FISH-negative, karyotype-negative acute promyelocytic leukemia.
Blood. 2023;142:1328.
PubMed

PRINCE HM
Blocked addiction to IL-15 for treating T-LGLL.
Blood. 2023;142:1258-1260.
PubMed

XIE J, Bao X, Xue SL, Shen H, et al
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
Blood. 2023;142:1323-1327.
PubMed

ZHANG J, Duan Y, Wu P, Chang Y, et al
Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia.
Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490.
PubMed Abstract available

KUMAR J, Petrova-Drus K
Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion.
Blood. 2023;142:1253.
PubMed

CHELOOR KOVILAKAM S, Gu M, Dunn WG, Marando L, et al
Prevalence and significance of DDX41 gene variants in the general population.
Blood. 2023;142:1185-1192.
PubMed Abstract available

YAMAMOTO S, Sanefuji M, Suzuki M, Sonoda Y, et al
Pediatric leukemia and maternal occupational exposure to anticancer drugs: The Japan Environment and Children's Study.
Blood. 2023 Oct 3:blood.2023021008. doi: 10.1182/blood.2023021008.
PubMed Abstract available

September 2023

GOEDE V
Frailty is also a target for targeted drugs in CLL.
Blood. 2023;142:1107-1108.
PubMed

VAN DER STRATEN L, Stege CAM, Kersting S, Nasserinejad K, et al
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood. 2023;142:1131-1142.
PubMed Abstract available

MERLI P, Algeri M, Galaverna F, Bertaina V, et al
TCRalphabeta/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.
Blood. 2023 Sep 22:blood.2023021336. doi: 10.1182/blood.2023021336.
PubMed Abstract available

LI S, Adams PD
Targeting the epichaperome to combat AML.
Blood. 2023;142:1031-1032.
PubMed

Gribben JG. Targeting the methylome to improve CLL outcome. Blood. 2023;142(1):4-6.
Blood. 2023;142:1103.
PubMed

CARTER BZ, Mak PY, Muftuoglu M, Tao W, et al
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Blood. 2023;142:1056-1070.
PubMed Abstract available

UCKELMANN HJ, Klusmann JH
Double trouble: IRAK1/4 inhibitors in AML/MDS.
Blood. 2023;142:945-946.
PubMed

KWOK M, Stankovic T
CLL patients: GIVe me three!
Blood. 2023;142:941-943.
PubMed

HUBER H, Tausch E, Schneider C, Edenhofer S, et al
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood. 2023;142:961-972.
PubMed Abstract available

BENNETT J, Ishikawa C, Agarwal P, Yeung J, et al
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Blood. 2023;142:989-1007.
PubMed Abstract available

FEI MY, Wang Y, Chang BH, Xue K, et al
The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.
Blood. 2023;142:903-917.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum